Genocea Biosciences Inc (GNCAQ)

[NY1972]

FATE

The open-label, multi-center phase I study is designed to assess the safety and activity of a single-dose treatment cycle of FT596 in up to four dose cohorts 30, 90, 300 and 900 million cells) as a monotherapy and in combination with CD20-targeted monoclonal antibody therapy for the treatment of relapsed / refractory B-cell malignancies.

Per the case study, a heavily pretreated patient with diffuse large B-cell lymphoma (DLBCL) achieved a partial response following administration of a single-dose treatment cycle of FT596 as a monotherapy in the first dose cohort of 30 million cells. In addition, the patient subsequently received a second single-dose treatment cycle of FT596, which led to a better response as evidenced by a further decrease in both tumor size and metabolic activity.

This particular patient had previously received seven prior treatment regimens including five rituximab-containing regimens as well as an autologous stem cell transplantation and was most recently refractory to an experimental cellular therapy.